Co‐treatment of the male partner in vaginal candidosis: a double‐blind randomized control study

Bisschop, M.P.J.M.; Merkus, J.M.W.M.; Scheygrond, H.; Cutsem, J. Van

doi:10.1111/j.1471-0528.1986.tb07818.x

Cited by 54 publications

(29 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Concomitant Prophylactic Therapy Of Male Partner?mentioning

confidence: 99%

“…However, concomitant antifungal therapy of the male sexual consort of women with RVVC has generally not been reported to have any in¯uence on the attack rate of RVVC 187 . For example, in a double-blind randomized study of 117 couples, cure and recurrence rates in women were not different with or without simultaneous treatment of male partners with various ketoconazole regimens 187 . In another double-blind randomized study, the recurrence rate was not statistically different in women with or without simultaneous treatment of male partners with a course of itraconazole 151 .…”

Section: Concomitant Prophylactic Therapy Of Male Partner?mentioning

confidence: 99%

See 1 more Smart Citation

Facts and myths on recurrent vulvovaginal candidosis—a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy

Rodrigues²,

et al. 2002

View full text Add to dashboard Cite

Summary:Approximately three-quarters of all women will experience an episode of vulvovaginal candidosis at least once in their life and 5± 10% of them will have more than one attack. Women suffering from three to four attacks within 12 months will be diagnosed with recurrent vulvovaginal candidosis (RVVC). This review covers the large number of proposed aetiological factors for RVVC. The diagnosis of the condition made by conventional means by health providers is often false and is also often misdiagnosed by the affected woman herself. The review covers various methods of diagnosing RVVC and the current knowledge on potential pathogenetic mechanisms proposed for genital candida infections. Treatment of RVVC, including local and systemic antimicrobial therapy and behaviour modi® cation to decrease the risk of recurrences, are discussed. Recent knowledge on drug resistance in candida is also included.

show abstract

Section: Concomitant Prophylactic Therapy Of Male Partner?mentioning

confidence: 99%

Section: Concomitant Prophylactic Therapy Of Male Partner?mentioning

confidence: 99%

Facts and myths on recurrent vulvovaginal candidosis—a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy

Rodrigues²,

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Recurrent disease in women is associated with presence of the same strains of Candida in their own oral cavity, gut, and mouth, but also in the gut, mouth or on the glans penis of their partners [2,3] . Still systematic treatment of men is not likely to improve the recurrence rate of candidosis in most women, showing that sexual transmission is rather seldom the primary cause of infection in women [4][5][6] . Furthermore, women without sexual activity present as often with acute and recurrent candidosis as their sexually active counterparts, and sexual promiscuity does not necessarily lead to a more frequent occurrence of candidosis, unless frequent antibiotics have been prescribed for other infections.…”

mentioning

confidence: 99%

Management of Recurrent Vulvo-Vaginal Candidosis as a Chronic Illness

Donders

Bellen²,

Mendling

2010

Gynecol Obstet Invest

View full text Add to dashboard Cite

For sporadic acute Candida vaginitis, any oral or local antifungal therapy can be used. For women with recurrent vulvo-vaginal candidosis (RVC), on the other hand, such simple approaches are insufficient, regardless of the product chosen. Instead, RVC should be managed as any other chronic disease and requires long-term, prophylactic, suppressive antifungal treatment. A regimen using individualized, decreasing doses of oral fluconazole (the ReCiDiF regimen) was proven to be highly efficient and offered great comfort to the patients. During this regimen, it is crucial that patients are carefully examined by anamnestic, clinical, microscopic and culture-proven absence of Candida. If a relapse occurs, the medication is adjusted and efforts are taken to find a possible triggering factor for the reactivation of the infection. Care has to be taken not to accumulate ‘don’t do’s’, unless the efficiency of a measure has been proven, by trying to eliminate one risk factor at a time for 2 months. Known possible triggers to be kept in mind are (1) antibiotic use, (2) use of specific contraceptives, especially combined contraceptive pills, (3) disturbed glucose metabolism, (4) the use of personal hygienic products, and (5) tight clothing or plastic panty liners. In therapy-resistant cases, non-albicans infection must be ruled out, and alternative therapies should be tried. Boric acid is proven to be efficient in most of these resistant cases, but other non-azoles like amphotericin B, flucytosine, gentian violet, and even caspofungin may have to be tried. As a final remark it has to be said that many patients feel poorly understood and inefficiently managed by many care-givers, increasing their feelings of guilt and sexual inferiority. Therefore, attention has to be given to take the disease seriously, follow strict treatment regimens, and advise precisely and based on individual evidence concerning any possible risk factors for recurrence. In case of therapy-resistant vulvo-vaginitis, reconsider your diagnosis and/or consider referral to specialized therapists.

show abstract

“…Bisschop et al (22) carried out a double-blind randomized clinical trial in Belgium with 117 women treated with 200 mg of ketoconazole twice a day for three days, whose partners were randomly treated with ketoconazole or placebo. Cure and recurrence rates were similar among women with treated (cure: 48/57 and recurrence: 13/48) or placebo partners (cure: 53/60 and recurrence: 19/53), as seen in Table 1.…”

Section: Vaginal Candidiasismentioning

confidence: 99%

Vulvovaginitis and the treatment of asymptomatic partners: a systematic review and meta-analysis

Giraldo¹,

Rodrigues²,

Gosson³

et al. 2014

J bras doenças sex transm

View full text Add to dashboard Cite

Introduction: Treating sexual partners of women with vaginal candidiasis and bacterial vaginosis is a discussed topic. Despite the recommendations of international guidelines, doctors are still known to treat asymptomatic partners. Objective: To evaluate the influence of asymptomatic partner treatment in the cure and recurrence of vulvovaginitis in women. Methods: The following databases were searched using Mesh terms: PubMed, Embase, SciELO and CINAHAL. The selection criteria included randomized clinical trials published from 1982 to 2012. Studies involving pregnant women were excluded. Methodological quality was assessed using Jadad's scale. Review Manager 5.1 was used for statistical analysis. Results: Eight randomized clinical trials were included based on the chosen criteria: 1,088 women were enrolled. For bacterial vaginosis, the relative risk for cure was 1.00 (95%CI 0.95-1.05, p=0.13), and for recurrence 0.84 (95%CI 0.62-1.14, p=0.34). Vaginal candidiasis had a RR of 1.03 (95%CI 0.94-1.14, p=0.48) for cure, and 1.02 (95%CI 0.77-1.33, p=0.91) for recurrence. Conclusion: Treatment of asymptomatic sexual partners of women with vaginal candidiasis or bacterial vaginosis does not affect the cure or recurrence rates and may increase the risk of side effects and unnecessary financial costs.

show abstract

Co‐treatment of the male partner in vaginal candidosis: a double‐blind randomized control study

Cited by 54 publications

References 4 publications

Facts and myths on recurrent vulvovaginal candidosis—a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy

Facts and myths on recurrent vulvovaginal candidosis—a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy

Management of Recurrent Vulvo-Vaginal Candidosis as a Chronic Illness

Vulvovaginitis and the treatment of asymptomatic partners: a systematic review and meta-analysis

Contact Info

Product

Resources

About